Nervgen Pharma Corp (NGENF)

$4.20 +0.05 (1.20%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 64,700
Avg Vol 164,420
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 73%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke and confirmatory SCI study....

Industry: Biotechnology
Sector: Healthcare
Phone: 778-731-1711
Address:
112-970 Burrard Street, Unit 1290, Vancouver, Canada
Tarquinjones
Tarquinjones Dec. 8 at 7:55 AM
$NGENF $NGENF ASIA summary • Company is in active discussions with FDA about breakthrough and/or accelerated approval
1 · Reply
NVG291Fan
NVG291Fan Dec. 6 at 7:13 PM
$NGENF Late August I asked Dr. Punnett why we didn’t request Orphan Drug status based on our subacute cohort and he said he would check into it (we have it from the EMA but not our FDA so it doesn’t do us a whole lot of good). The original plan, per Kelly, was to pursue expedited approval based on chronic only if the results were good. We know the chronic results were good, and my feeling is that the subacute results must look good too - Therefore the company is waiting for the subacute results before the formal FDA Type A end of phase 2 meeting where we’ll probably pursue OD designation. Chronic wouldn’t get us that designation, but an effective treatment for the roughly 17,000 per year SCIs might. ODD benefits are below:
1 · Reply
kenridge
kenridge Dec. 5 at 7:29 PM
$NGENF accurate summary.one interesting point - I pay attention to phrasing, terms used - to see if there's any tell beyond what is stated. Two observations: 1) CEO took time to explain the increased rigor associated with climbing the ladder of FDA designations, alluding this being a hot current topic, punctuating with 'having active discussions with the FDA on these points' right now. My take - he's expecting BTD, and believes AA is more than viable. 2) in thanking all participants, clinicians and Dr Perez for their support in the study, he continually referenced the CONNECt study in the past tense -multiple times. As a listener, it would sound as if it's completed. My take - strikes me he wouldn't reference it as such if the study were still enrolling with a distance to go. My guess is that we won't hear LPE, may not hear LPLV. Possible the end of the trial is closer than we think.
1 · Reply
aladdinscarpet
aladdinscarpet Dec. 5 at 6:19 PM
$NGENF ASIA summary • Company is in active discussions with FDA about breakthrough and/or accelerated approval • Next trial: Planning a large, multi-site, function-focused pivotal trial (effectively phase 3) starting ~summer 2026, with up to ~60 sites worldwide. • Endpoint strategy: Phase 1b/2a was biologic proof-of-concept (MEP + safety); the pivotal trial will be built around functional recovery and independence (e.g., GRASSP), with MEP as a key biomarker. • NVG-291 is framed as a neurotrauma platform (SCI first, but also MS/stroke/ALS-relevant)
3 · Reply
Lytnup
Lytnup Dec. 5 at 5:10 PM
$NGENF ASIA webinar starting
2 · Reply
dave871
dave871 Dec. 5 at 3:25 PM
$NGENF NVG looks to have robust potential for MS. There is very similar MOA regarding ptp/cspg/oligodendrocytes…remyelination.. -side note- Brad Lang is now with Convelo therapeutics (working on remyelination) was a co-founder/developer of NVG with Jerry Silver at CWRU. Interesting stuff…
1 · Reply
cninc
cninc Dec. 5 at 4:05 AM
$NGENF I think everyone has been seeing those articles floating around talking about focused ultrasound treatment for ALZ ? Well tonight I had a little talk with Grok and he seems to think that the reason it works is that it breaks up CSPG's from around amyloid plaques and tangles and help dissolve them. Too much to cut and paste to here, but check it out sometime, you'll see a lot of science info that we're used to and even some references back to NVG-291. Very interesting stuff.
0 · Reply
philmitchell
philmitchell Dec. 5 at 12:25 AM
$NGENF https://www.statnews.com/2025/12/04/fda-considers-single-clinical-trial-for-new-product-approvals/
0 · Reply
NVG291Fan
NVG291Fan Dec. 4 at 8:23 PM
$NGENF It would be nice to see an update on Clay. Now that the quarterly update pretty much confirmed he received the drug and not placebo, it’s a bit surprising we haven’t heard anything in almost a year from his family. Wasn’t Snoop Dog in one of his initial videos?
1 · Reply
Richardo8586
Richardo8586 Dec. 4 at 7:54 PM
$NGENF You are wrong. The only way you would be right was if we lived on an alternate universe. But "A" for effort!
1 · Reply
Latest News on NGENF
No data available.
Tarquinjones
Tarquinjones Dec. 8 at 7:55 AM
$NGENF $NGENF ASIA summary • Company is in active discussions with FDA about breakthrough and/or accelerated approval
1 · Reply
NVG291Fan
NVG291Fan Dec. 6 at 7:13 PM
$NGENF Late August I asked Dr. Punnett why we didn’t request Orphan Drug status based on our subacute cohort and he said he would check into it (we have it from the EMA but not our FDA so it doesn’t do us a whole lot of good). The original plan, per Kelly, was to pursue expedited approval based on chronic only if the results were good. We know the chronic results were good, and my feeling is that the subacute results must look good too - Therefore the company is waiting for the subacute results before the formal FDA Type A end of phase 2 meeting where we’ll probably pursue OD designation. Chronic wouldn’t get us that designation, but an effective treatment for the roughly 17,000 per year SCIs might. ODD benefits are below:
1 · Reply
kenridge
kenridge Dec. 5 at 7:29 PM
$NGENF accurate summary.one interesting point - I pay attention to phrasing, terms used - to see if there's any tell beyond what is stated. Two observations: 1) CEO took time to explain the increased rigor associated with climbing the ladder of FDA designations, alluding this being a hot current topic, punctuating with 'having active discussions with the FDA on these points' right now. My take - he's expecting BTD, and believes AA is more than viable. 2) in thanking all participants, clinicians and Dr Perez for their support in the study, he continually referenced the CONNECt study in the past tense -multiple times. As a listener, it would sound as if it's completed. My take - strikes me he wouldn't reference it as such if the study were still enrolling with a distance to go. My guess is that we won't hear LPE, may not hear LPLV. Possible the end of the trial is closer than we think.
1 · Reply
aladdinscarpet
aladdinscarpet Dec. 5 at 6:19 PM
$NGENF ASIA summary • Company is in active discussions with FDA about breakthrough and/or accelerated approval • Next trial: Planning a large, multi-site, function-focused pivotal trial (effectively phase 3) starting ~summer 2026, with up to ~60 sites worldwide. • Endpoint strategy: Phase 1b/2a was biologic proof-of-concept (MEP + safety); the pivotal trial will be built around functional recovery and independence (e.g., GRASSP), with MEP as a key biomarker. • NVG-291 is framed as a neurotrauma platform (SCI first, but also MS/stroke/ALS-relevant)
3 · Reply
Lytnup
Lytnup Dec. 5 at 5:10 PM
$NGENF ASIA webinar starting
2 · Reply
dave871
dave871 Dec. 5 at 3:25 PM
$NGENF NVG looks to have robust potential for MS. There is very similar MOA regarding ptp/cspg/oligodendrocytes…remyelination.. -side note- Brad Lang is now with Convelo therapeutics (working on remyelination) was a co-founder/developer of NVG with Jerry Silver at CWRU. Interesting stuff…
1 · Reply
cninc
cninc Dec. 5 at 4:05 AM
$NGENF I think everyone has been seeing those articles floating around talking about focused ultrasound treatment for ALZ ? Well tonight I had a little talk with Grok and he seems to think that the reason it works is that it breaks up CSPG's from around amyloid plaques and tangles and help dissolve them. Too much to cut and paste to here, but check it out sometime, you'll see a lot of science info that we're used to and even some references back to NVG-291. Very interesting stuff.
0 · Reply
philmitchell
philmitchell Dec. 5 at 12:25 AM
$NGENF https://www.statnews.com/2025/12/04/fda-considers-single-clinical-trial-for-new-product-approvals/
0 · Reply
NVG291Fan
NVG291Fan Dec. 4 at 8:23 PM
$NGENF It would be nice to see an update on Clay. Now that the quarterly update pretty much confirmed he received the drug and not placebo, it’s a bit surprising we haven’t heard anything in almost a year from his family. Wasn’t Snoop Dog in one of his initial videos?
1 · Reply
Richardo8586
Richardo8586 Dec. 4 at 7:54 PM
$NGENF You are wrong. The only way you would be right was if we lived on an alternate universe. But "A" for effort!
1 · Reply
Logic102
Logic102 Dec. 4 at 6:33 PM
$NGENF I agree with several others here that NervGen has the lead in the SCI space for now and has an exciting product. I still think LCTX is a better buy right now, not because of SCI but due to its OpRegen progress and Partnership with Roche for Age Related Dry Macular Degeneration which should be moving to P3 fairly soon. Both companies have other irons in the fire as well, but nothing very far along or totally proven. I own both, more overweight LCTX. You can tell me why I'm wrong; I welcome your feedback.
2 · Reply
Logic102
Logic102 Dec. 4 at 3:52 PM
$NGENF Keep a watch on news related to the company receiving a CIRM grant from the State of California. LCTX recently filed it has been denied and will resubmit a new application. It appears that NervGen is developing a technological and trial progress lead in this space. Thoughts?
1 · Reply
MetalinMaybach
MetalinMaybach Dec. 4 at 2:40 PM
$NGENF Do we think there will be any new information or updates provided in tomorrow’s webinar?
0 · Reply
rwelsh633
rwelsh633 Dec. 4 at 12:08 AM
$NGENF Larry Williams sharing an update… “ a lot of new nerve growth”!!!
1 · Reply
aladdinscarpet
aladdinscarpet Dec. 3 at 11:10 PM
$NGENF Here we sit with 867 followers, with a story where the economics rival CAPR (up 370% on data today), with data from small N trial that reached stat sig on a primary endpoint that is probably a surrogate marker of effectiveness (relevant for accelerated approval), a clean safety profile, a well-researched mechanism of action, and plenty of follow-on indications. The rewards of this journey, both human and financial, have just begun.Looking forward to the ASIA symposium generating more excitement, NASDAQ listing, readout of subacute arm of CONNECTSCI, and more. It’s going to be quite a ride. We’ll look back in a year and today’s prices will seem ridiculously low.
1 · Reply
NVG291Fan
NVG291Fan Dec. 3 at 10:00 PM
$NGENF Look at the five year SP for this little bio compared to 99.9% of the other little bios. We have a dedicated group of investors and I predict the next two months will be very exciting.
0 · Reply
aladdinscarpet
aladdinscarpet Dec. 3 at 7:18 PM
$NGENF Power hour rally? Not much selling pressure (yet)…
2 · Reply
ReggieTrades
ReggieTrades Dec. 3 at 6:56 PM
$NGENF @cninc guess where my CAPR dividend is going...
2 · Reply
Mammazallata
Mammazallata Dec. 3 at 6:48 PM
$NGENF I think we have seen most of the movement already! From now
1 · Reply
WhatWillB
WhatWillB Dec. 3 at 5:45 PM
$NGENF “Push push…”
0 · Reply
MarianoItaliano
MarianoItaliano Dec. 3 at 3:08 PM
$NGENF Crazy we're still not ath but I think we will be by the eoy
3 · Reply
CCbank
CCbank Dec. 2 at 7:45 PM
$NGENF Spartans, Ready Your Breakfast And Eat Hardy, For Tonight We Dine In Hell!! Glory is upon us!!! 5 and We Never look Back !!!
0 · Reply